Will Heidi Overton be confirmed as FDA Commissioner by September 30?
BUY YES
- Cost
- 6.9¢
- Implied chance
- 6.9%
- Return if right
- 1349.3%
- Spread cost
- 12%
If you put in $100
You get 1449.3 shares at 6.9¢ each.
YES wins: $1449.28 back, a profit of $1349.28. YES loses: $0.00, and the whole $100 is gone.
The gap between buyers and sellers takes $190.07 of that profit. Without it you would make $1539.34.
Assumes the whole order fills at this price. A large order eats into the book and averages worse.
Buy YES on Polymarket
BUY NO
- Cost
- 94.7¢
- Implied chance
- 94.7%
- Return if right
- 5.6%
- Spread cost
- 14%
If you put in $100
You get 105.6 shares at 94.7¢ each.
NO wins: $105.60 back, a profit of $5.60. NO loses: $0.00, and the whole $100 is gone.
The gap between buyers and sellers takes $0.90 of that profit. Without it you would make $6.50.
Assumes the whole order fills at this price. A large order eats into the book and averages worse.
Buy NO on Polymarket
Latest: Oct 6, 05:44 AM
Latest news
headlines link to their publishers- I'm 25 with a terminal disease. We need an FDA commissioner that hears people like meFox News · 8d ago
- Abortion Pills, Vaccines and Food Safety: F.D.A. Nominee Heidi Overton Faces Senate Confirmation HearingThe New York Times · 12d ago
- Dr. Scott Gottlieb says Trump FDA pick Heidi Overton "could be a strong candidate"CBS News · 1mo ago
Headlines are matched on the names in “Will Heidi Overton be confirmed as FDA Commissioner by Septe…”. Nobody checks them by hand, so one may not be relevant. They also say nothing about whether the price has already moved on this news.
How this market resolves
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.